R J Glassock

Summary

Country: USA

Publications

  1. ncbi request reprint The emergence of the discipline of renal immunopathology
    Richard J Glassock
    UCLA School of Medicine, Los Angeles, California, USA
    Am J Nephrol 22:248-53. 2002
  2. ncbi request reprint The treatment of idiopathic membranous nephropathy: a dilemma or a conundrum?
    Richard J Glassock
    Am J Kidney Dis 44:562-6. 2004
  3. ncbi request reprint Uremic toxins: what are they? An integrated overview of pathobiology and classification
    Richard J Glassock
    Department of Internal Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
    J Ren Nutr 18:2-6. 2008
  4. ncbi request reprint IgA nephropathy: challenges and opportunities
    Richard J Glassock
    David Geffen School of Medicine, The University of California at Los Angeles, USA
    Cleve Clin J Med 75:569-76. 2008
  5. doi request reprint An update on glomerular disease in the elderly
    Richard J Glassock
    Department of Medicine, The David Geffen School of Medicine, UCLA, Laguna Niguel, Los Angeles, CA 92677, USA
    Clin Geriatr Med 29:579-91. 2013
  6. doi request reprint Pathogenesis of membranous nephropathy: a new paradigm in evolution
    Richard J Glassock
    Contrib Nephrol 181:131-42. 2013
  7. doi request reprint Therapy of relapsing minimal-change disease in adults: a new approach?
    Richard J Glassock
    David Geffen School of Medicine at UCLA, 8 Bethany, Laguna Niguel, Los Angeles, California 92677, USA
    Kidney Int 83:343-5. 2013
  8. doi request reprint Idiopathic membranoproliferative glomerulonephritis: does it exist?
    Fernando C Fervenza
    Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Nephrol Dial Transplant 27:4288-94. 2012
  9. pmc The implications of anatomical and functional changes of the aging kidney: with an emphasis on the glomeruli
    Richard J Glassock
    Geffen School of Medicine at UCLA, Los Angeles, California 92677, USA
    Kidney Int 82:270-7. 2012
  10. doi request reprint The pathogenesis of membranous nephropathy: evolution and revolution
    Richard J Glassock
    Geffen School of Medicine, University of California, Los Angeles, California, USA
    Curr Opin Nephrol Hypertens 21:235-42. 2012

Detail Information

Publications44

  1. ncbi request reprint The emergence of the discipline of renal immunopathology
    Richard J Glassock
    UCLA School of Medicine, Los Angeles, California, USA
    Am J Nephrol 22:248-53. 2002
  2. ncbi request reprint The treatment of idiopathic membranous nephropathy: a dilemma or a conundrum?
    Richard J Glassock
    Am J Kidney Dis 44:562-6. 2004
  3. ncbi request reprint Uremic toxins: what are they? An integrated overview of pathobiology and classification
    Richard J Glassock
    Department of Internal Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
    J Ren Nutr 18:2-6. 2008
    ..In addition, this article will attempt to integrate these disparate phenomena into a systems biology approach as to how such toxins lead to the diverse clinical manifestations so characteristic of the uremic state...
  4. ncbi request reprint IgA nephropathy: challenges and opportunities
    Richard J Glassock
    David Geffen School of Medicine, The University of California at Los Angeles, USA
    Cleve Clin J Med 75:569-76. 2008
    ..But at the same time, opportunities abound for new tests and treatments that may eventually lead to control of this common form of chronic kidney disease...
  5. doi request reprint An update on glomerular disease in the elderly
    Richard J Glassock
    Department of Medicine, The David Geffen School of Medicine, UCLA, Laguna Niguel, Los Angeles, CA 92677, USA
    Clin Geriatr Med 29:579-91. 2013
    ..Effective treatment regimens are available to ameliorate the adverse consequences of acute, progressive, and chronic glomerular disease in the geriatric population. ..
  6. doi request reprint Pathogenesis of membranous nephropathy: a new paradigm in evolution
    Richard J Glassock
    Contrib Nephrol 181:131-42. 2013
    ..Most forms of secondary MN appear to be due to distinctly different pathogenetic mechanisms...
  7. doi request reprint Therapy of relapsing minimal-change disease in adults: a new approach?
    Richard J Glassock
    David Geffen School of Medicine at UCLA, 8 Bethany, Laguna Niguel, Los Angeles, California 92677, USA
    Kidney Int 83:343-5. 2013
    ..However, the optimal dosing regimen and mechanism of action remain unclear. Thus, randomized controlled trials are warranted in both adults and children to better define the role of rituximab in multiple-relapsing MCD...
  8. doi request reprint Idiopathic membranoproliferative glomerulonephritis: does it exist?
    Fernando C Fervenza
    Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Nephrol Dial Transplant 27:4288-94. 2012
    ..Idiopathic MPGN remains an 'endangered species' after its separation from these known causes...
  9. pmc The implications of anatomical and functional changes of the aging kidney: with an emphasis on the glomeruli
    Richard J Glassock
    Geffen School of Medicine at UCLA, Los Angeles, California 92677, USA
    Kidney Int 82:270-7. 2012
    ..This review describes important shortcomings and deficiencies with our current approach and understanding of CKD in the older and elderly adult...
  10. doi request reprint The pathogenesis of membranous nephropathy: evolution and revolution
    Richard J Glassock
    Geffen School of Medicine, University of California, Los Angeles, California, USA
    Curr Opin Nephrol Hypertens 21:235-42. 2012
    ..This review analyzes the recent developments in understanding the pathogenesis of the primary and secondary forms of membranous nephropathy...
  11. doi request reprint Attending rounds: an older patient with nephrotic syndrome
    Richard J Glassock
    David Geffen School of Medicine, University of California, Los Angeles, USA
    Clin J Am Soc Nephrol 7:665-70. 2012
    ....
  12. doi request reprint Left ventricular mass in chronic kidney disease and ESRD
    Richard J Glassock
    The David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Clin J Am Soc Nephrol 4:S79-91. 2009
    ..In the meantime, key management principles designed to ameliorate LVH and its complications should become a routine part of the care of the patients with CKD and ESRD...
  13. pmc Ageing and the glomerular filtration rate: truths and consequences
    Richard J Glassock
    8 Bethany, Laguna Niguel, CA 92677, USA
    Trans Am Clin Climatol Assoc 120:419-28. 2009
    ..This paper discusses the known effects of ageing on GFR and the consequences of using a classification system for defining CKD that does not take into account the normal decline of GFR with ageing...
  14. doi request reprint Glomerular disease in the elderly
    Richard J Glassock
    The David Geffen School of Medicine at UCLA, 8 Bethany, Laguna Niguel, Los Angeles, CA 92677, USA
    Clin Geriatr Med 25:413-22. 2009
    ..This article briefly outlines the common presentations of glomerular disease in the elderly and discusses the clinical features, prognosis, and management of the primary and secondary glomerular diseases in this population of patients...
  15. pmc Analyzing antibody activity in IgA nephropathy
    Richard J Glassock
    UCLA David Geffen School of Medicine, Los Angeles, California, USA
    J Clin Invest 119:1450-2. 2009
    ..These IgG autoantibodies displayed remarkably restricted heterogeneity. These observations offer new insights into disease pathogenesis and may lead to new methods of diagnosis, monitoring, and therapy for patients with IgA nephropathy...
  16. doi request reprint The pathogenesis of IgA nephropathy
    Richard J Glassock
    David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Curr Opin Nephrol Hypertens 20:153-60. 2011
    ..This review will analyze contemporary information concerning the possible pathogenetic mechanisms involved in IgA nephropathy, emphasizing studies in humans rather than experimental animals...
  17. doi request reprint Diagnosing chronic kidney disease
    Richard J Glassock
    David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Curr Opin Nephrol Hypertens 19:123-8. 2010
    ..To review the current state-of-the art in diagnosing chronic kidney disease (CKD) using classification systems based on estimated glomerular filtration rate (eGFR) and kidney damage...
  18. doi request reprint The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey
    Richard J Glassock
    David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Am J Kidney Dis 56:157-67. 2010
    ..It is hoped that this 50-year odyssey will culminate in real progress in the diagnosis, prognosis, and therapy for the human disease...
  19. doi request reprint Health care reforms in America: perspectives, comparisons and realities
    R J Glassock
    David Geffen School of Medicine, Los Angeles, CA, USA
    QJM 103:709-14. 2010
    ....
  20. pmc Is the presence of microalbuminuria a relevant marker of kidney disease?
    Richard J Glassock
    David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Curr Hypertens Rep 12:364-8. 2010
    ..This article reviews the current evidence concerning MA as a marker of kidney disease or kidney damage...
  21. doi request reprint Uremia (end-stage renal disease): how cost-effective are preventive strategies?
    Richard J Glassock
    Department of Medicine, The David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    J Ren Nutr 20:S131-4. 2010
    ..Newer strategies involving statins and new combinations of agents are emerging but have not yet been tested for their cost-effectiveness in preventing ESRD cost-effectiveness...
  22. doi request reprint The 2010 nephrology quiz and questionnaire: part 1
    Richard J Glassock
    David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Clin J Am Soc Nephrol 6:2318-27. 2011
    ..These articles try to recapitulate the session and reproduce its educational value for a larger audience--the readers of the Clinical Journal of the American Society of Nephrology. Have fun...
  23. doi request reprint The 2010 nephrology quiz and questionnaire: part 2
    Richard J Glassock
    David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Clin J Am Soc Nephrol 6:2534-47. 2011
    ..These articles try to recapitulate the session and reproduce its educational value for a larger audience--that of the readers of the Clinical Journal of the American Society of Nephrology. Have fun...
  24. doi request reprint Estimated glomerular filtration rate: time for a performance review?
    Richard J Glassock
    Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Kidney Int 75:1001-3. 2009
    ..eGFR formulae also contain variables that independently influence the risk of CKD and cardiovascular disease. eGFR needs a performance review to foster its evolution as a clinically useful tool...
  25. ncbi request reprint Diagnosis and natural course of membranous nephropathy
    Richard J Glassock
    Geffen School of Medicine at UCLA, Los Angeles, CA 92677, USA
    Semin Nephrol 23:324-32. 2003
    ....
  26. ncbi request reprint The early history of chemical immunosuppression: 1900-1965
    Richard J Glassock
    J Nephrol 19:S132-6. 2006
    ..The paper discusses the role of serendipity in the advent of 6-mercapthopurine (6-MP) therapy and the productivity in the field through Nobel Prize recipients...
  27. ncbi request reprint Secondary minimal change disease
    Richard J Glassock
    The Geffen School of Medicine at UCLA, California, USA
    Nephrol Dial Transplant 18:vi52-8. 2003
    ..The predisposing conditions include neoplastic diseases, toxic or allergic reactions to drugs, infections, auto-immune disorders and other miscellaneous entities. These disorders are reviewed and catalogued in this contribution...
  28. ncbi request reprint Concluding remarks
    Richard J Glassock
    The David Geffen School of Medicine at UCLA, Los Angeles, Calif, USA
    Contrib Nephrol 157:169-73. 2007
  29. ncbi request reprint Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum
    Richard J Glassock
    University of California Los Angeles, USA
    J Am Soc Nephrol 18:2221-5. 2007
    ..The optimal duration of prophylactic anticoagulation is unknown but very likely extends to the duration of the nephrotic state per se...
  30. ncbi request reprint An epidemic of chronic kidney disease: fact or fiction?
    Richard J Glassock
    David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Nephrol Dial Transplant 23:1117-21. 2008
  31. doi request reprint Routine reporting of estimated glomerular filtration rate: not ready for prime time
    Richard J Glassock
    David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Nat Clin Pract Nephrol 4:422-3. 2008
  32. doi request reprint Screening for CKD with eGFR: doubts and dangers
    Richard J Glassock
    David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Clin J Am Soc Nephrol 3:1563-8. 2008
    ....
  33. doi request reprint The global burden of chronic kidney disease: how valid are the estimates?
    Richard J Glassock
    David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Nephron Clin Pract 110:c39-46; discussion c47. 2008
    ..Current classification schemas may overstate the prevalance of CKD. This minireview analyzes the pitfalls in the use of current classification approaches for identifying CKD on a global basis...
  34. ncbi request reprint The rising tide of end-stage renal disease: what can be done?
    Richard J Glassock
    8 Bethany, Laguna Niguel, CA 92677, USA
    Clin Exp Nephrol 8:291-6. 2004
    ..If these strategies can be implemented at the societal level and compliance with the interventions is robust, it is entirely possible that the rising tide of ESRD can be converted into a receding tide of ESRD in the future...
  35. ncbi request reprint Glomerular therapeutics: looking back, looking forward
    R J Glassock
    UCLA School of Medicine, Los Angeles, California 92677, USA
    Heart Dis 3:276-81. 2001
    ..Eventually, the understanding of the genetic basis of susceptibility to glomerular disease and its progression will allow a preventative and curative, rather than palliative, strategy to emerge...
  36. ncbi request reprint Nephrology in the 21st century: revolutionary changes
    R J Glassock
    UCLA School of Medicine, Los Angeles, CA, USA
    Am J Kidney Dis 35:S90-2. 2000
    ..The organization of medical practice will evolve into new, integrated systems of care. The disparity between the "haves" and the "have-nots" will widen. Profound challenges and opportunities await nephrology in the new millennium...
  37. doi request reprint Posttransplant recurrence of primary glomerulonephritis
    Claudio Ponticelli
    Division of Nephrology, Scientific Institute Humanitas, Milan, Italy
    Clin J Am Soc Nephrol 5:2363-72. 2010
    ....
  38. doi request reprint Recurrence of secondary glomerular disease after renal transplantation
    Claudio Ponticelli
    Division of Nephrology, Scientific Institute Humanitas, Rozzano, Milano, Italy
    Clin J Am Soc Nephrol 6:1214-21. 2011
    ..The main issues in transplantation of patients with secondary GN are the infectious, cardiovascular, or hepatic complications associated with the original disease or its treatment...
  39. doi request reprint CKD in the elderly
    Richard J Glassock
    Am J Kidney Dis 52:803; author reply 803-4. 2008
  40. pmc Rosuvastatin: an independent analysis of risks and benefits
    Douglas P Zipes
    Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, USA
    MedGenMed 8:73. 2006
    ..Although the effectiveness of statins is well established, analyses of spontaneous adverse event reports have recently questioned the safety of rosuvastatin...
  41. ncbi request reprint L-carnitine use in dialysis patients: is national coverage for supplementation justified? What were CMS regulators thinking--or were they?
    Theodore I Steinman
    Nephrol News Issues 17:28-30, 32-4, 36 passim. 2003
    ..Until there is scientific evidence to support use of L-carnitine supplementation, and it proves to be cost-effective, reimbursement is not justified. Therefore, the current CMS reimbursement decision for L-carnitine appears to be flawed...
  42. ncbi request reprint Circulating permeability factors in the nephrotic syndrome: a fresh look at an old problem
    Richard J Glassock
    J Am Soc Nephrol 14:541-3. 2003
  43. ncbi request reprint Prevention of microalbuminuria in type 2 diabetes: millimeters or milligrams?
    Richard J Glassock
    J Am Soc Nephrol 17:3276-8. 2006
  44. ncbi request reprint Multitarget therapy of lupus nephritis: base hit or home run?
    Richard J Glassock
    J Am Soc Nephrol 19:1842-4. 2008